Bioxytran Provides Corporate Update Highlighting Momentum Across Its Multi-Platform Pipeline
Company reiterates focus on advancing ProLectin‑M under an active FDA IND and progressing oxygen-transport programs for stroke and neurodegenerative diseases NEEDHAM, MASS., Jan 29, 2026 – (ACN Newswire via SeaPRwire.com) — Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform technologies spanning glycovirology, hypoxia, and degenerative diseases, today issued a […]